Searched over 200M research papers
10 papers analyzed
These studies suggest that both metoprolol and lisinopril effectively reduce blood pressure, with lisinopril showing additional benefits in arterial distensibility and quality of life, while metoprolol is particularly effective post-myocardial infarction and in combination therapy for heart failure.
19 papers analyzed
Both metoprolol and lisinopril are effective in reducing blood pressure in patients with hypertension. In a study comparing their efficacy, lisinopril (40-80 mg/day) and metoprolol (100-200 mg/day) both significantly reduced diastolic blood pressure (DBP) from baseline values. However, lisinopril demonstrated a greater reduction in systolic blood pressure (SBP) compared to metoprolol, with a statistically significant difference observed at both week 4 and week 8 of treatment.
In another study, both drugs were effective in maintaining reduced blood pressure over a 10-week period. Lisinopril reduced blood pressure from 173/102 mm Hg to 155/85 mm Hg, while metoprolol reduced it from 167/102 mm Hg to 153/84 mm Hg. This indicates that both medications are effective for long-term blood pressure control, though the differences in their impact on systolic pressure may influence the choice of treatment.
Lisinopril has been shown to improve arterial distensibility significantly more than metoprolol. In a study measuring the distensibility of the left common carotid artery, lisinopril significantly increased the percent change in diameter and distensibility, whereas metoprolol did not show such improvements. This suggests that lisinopril may have additional benefits in improving arterial health beyond blood pressure reduction.
Long-term treatment with lisinopril also improved forearm hemodynamics, increasing compliance and reducing vascular resistance, effects that were not observed with metoprolol. These improvements persisted even after treatment withdrawal, indicating a lasting benefit of lisinopril on vascular function.
Patients treated with lisinopril reported better quality of life outcomes compared to those treated with metoprolol. In a study assessing emotional, cognitive, and social functioning, lisinopril was found to be superior in some aspects of quality of life. This could be an important consideration for long-term treatment adherence and overall patient well-being.
Both medications were generally well-tolerated, but lisinopril had a slightly better side effect profile. Fewer patients discontinued lisinopril due to adverse events compared to metoprolol . Common side effects for metoprolol included fatigue, somnolence, and bronchospasm, while lisinopril was associated with headaches and dizziness.
In a large retrospective study, patients on valsartan had a lower risk of major cardiovascular or renal events compared to those on extended-release metoprolol, though the difference between valsartan and lisinopril was not statistically significant. This suggests that while metoprolol is effective, other medications like lisinopril or valsartan might offer additional protective benefits against cardiovascular events.
Combining lisinopril with metoprolol in patients with congestive heart failure (CHF) showed significant improvements in cardiac function, including reductions in left ventricular diastolic diameter and increases in ejection fraction . This combination therapy was well-tolerated and provided substantial clinical benefits, indicating a potential synergistic effect when both drugs are used together.
Both metoprolol and lisinopril are effective antihypertensive agents with distinct profiles. Lisinopril offers superior benefits in arterial distensibility, systolic blood pressure reduction, and quality of life, with a slightly better side effect profile. Metoprolol remains a valuable option, particularly in combination therapy for heart failure. The choice between these medications should be tailored to individual patient needs, considering both efficacy and tolerability.
Most relevant research papers on this topic